New drug duo tested for Tough-to-Treat lung cancer
NCT ID NCT03202940
Summary
This study is testing whether adding a second drug, cobimetinib, to the standard drug alectinib can help control advanced lung cancer that has stopped responding to alectinib alone. Researchers want to find the safest dose of this combination and see if it can shrink tumors or slow the cancer's growth. The study is for adults with a specific type of lung cancer (ALK-positive) that has spread and worsened despite prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.